Sign In
Buy TOMDF
$0.000001
+0 (+0%)
At Close: Jun 02, 2026
Todos Medical to Present at The LD Micro Conference
01:02pm, Monday, 06'th Jun 2022
New York, NY, and Tel Aviv, ISRAEL, June 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, tod
Todos Medical academic partner fully enrolls second cohort of LymPro Alzheimer's Blood Test trial
10:05am, Friday, 03'rd Jun 2022
Todos Medical Ltd has announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for the second cohort of the ongoing clinical trial to evaluate the co
Todos Medical says dietary supplement Tollovid has beneficial effect in long COVID case study after 26 days
11:12am, Wednesday, 01'st Jun 2022
Todos Medical Ltd majority-owned subsidiary 3CL Pharma Ltd has reported a Day 26 update from an ongoing 60-day case study of the dietary supplement 3CL protease inhibitor Tollovid in a patient experie
Todos Medical Ltd's CEO Gerald Commissiong has provided investors with an update on the company's CLIA/CAP-certified lab Provista Diagnostics, its 3CL Pharma majority-owned subsidiary progress, and pl
Todos Medical Ltd. (OTCQB:TOMDF) has revealed that its majority-owned subsidiary 3CL Pharma will present final data from the phase 2 clinical trial of Tollovir in the treatment of hospitalized severe
New York, NY, and Tel Aviv, ISRAEL, May 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today
A patient suffering from COVID-19 rebound symptoms after a round of treatment with Pfizer Inc (NYSE:PFE)'s (Pfizer Inc (NYSE:PFE)) pill Paxlovid started taking the dietary supplement Tollovoid from To
Todos Medical receives certificate of free sale for Tollovid Maximum Strength supplement
12:23pm, Monday, 02'nd May 2022
Todos Medical Ltd announced that its subsidiary 3CL Pharma Ltd has received a new certificate of free sale (CFS) for its Tollovid dietary supplement. The CFS from the US Food & Drug Administration pr
Todos Medical says set for study to assess potential product development of Tollovid to treat COVID-19 and Long COVID-19
10:43am, Wednesday, 27'th Apr 2022
Todos Medical Ltd. (OTCQB:TOMDF) has said it is poised to carry out a study on whether there is enough evidence to support a potential product development program for its Tollovid and/or Tollovid Dai
Todos Medical to Present at the Emerging Growth Conference
10:51am, Monday, 25'th Apr 2022
- Wednesday, April 27, 2022 at 10:00am – 10:45am EST -
Todos Medical launches web invitation for Long COVID clinical study and offers further patient case study
09:30am, Wednesday, 20'th Apr 2022
Todos Medical Ltd. (OTCQB:TOMDF) announced that it has launched a website for physicians and pediatricians to opt for their patients to take part in a Long COVID clinical study of its supplement prod
Todos Medical says Tollovid receives LGC Group's Informed Sport Certification as it targets athlete support
08:13am, Tuesday, 19'th Apr 2022
Todos Medical Ltd. (OTCQB:TOMDF) has announced that its majority-owned subsidiary 3CL Pharma Ltd has received LGC Group's Informed Sport Certification for Tollovid, its proprietary 3CL protease inhibi
Todos Medical hails White House initiative on Long COVID; says US FDA granted new certificate of free sale for Tollovid
02:34pm, Wednesday, 06'th Apr 2022
Todos Medical Ltd revealed that the US FDA recently granted a new Certificate of Free Sale for its dietary supplement product Tollovid as the diagnostic group hailed the US government's plans to ramp
Todos Medical says Tollovir and Tollovid show robust inhibitory activity against 3CL protease of strains of Omicron variant
10:35am, Monday, 04'th Apr 2022
Todos Medical Ltd said its majority-owned subsidiary 3CL Pharma Ltd announced that its mechanism-based 3CL protease inhibitors Tollovir and Tollovidthat target the active site of the 3CL protease --
Todos Medical lifts revenue by 136% in 2021, driven by COVID-19 testing
12:48pm, Friday, 01'st Apr 2022
Todos Medical Ltd said 2021 was a "strong year" for the company, which saw it increase revenue by 136% to $12.28 million, compared to $5.21 million in 2020. Posting results for the full year and fourt
